Tolerability of oral dextromethorphan in patients with a history of brain ischemia.
Twelve patients with a history of cerebral ischemia were randomized to treatment with the N-methyl-D-aspartate antagonist dextromethorphan (60 or 90 mg p.o. q.i.d.) or placebo for 2 weeks in a randomized, safety study. Neuropsychological testing did not detect evidence of cognitive dysfunction; however, side effects including lightheadedness, drowsiness, nausea, decreased coordination, and unsteady gait were reported by several patients while taking dextromethorphan.
Albers
G W
GW
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Palo Alto, CA.
Sáenz
R E
RE
Moses
J A
JA
D000368:Aged; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D003915:Dextromethorphan / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D011569:Psychiatric Status Rating Scales
D016202:N-Methylaspartate; D003915:Dextromethorphan